Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
12 years and counting yet nothing…
Go back to StockTwits you fool! And yeah it’s the weekend!!
Reverse merge on deck bitches
The 10 year nightmare continues! Far from an investment has always been a trade!!
Lol that’s wrong!
Majority of investors got scammed here!
Pipe dream of ever being released! Sorry to say!
Company as a whole has been incompetent for the last 10 years!
Lol why sell! Price is at 1.20 pre split!
Still no PR from company to back up George’s tweet that’s why price didn’t hold!
Haven’t sold a share...been adding on the dips. This is just the early stages of something good! Most important issue for me is that the company will not dilute this year!!
Just throwing this out there: maybe JT wants to sell but the Baker Bros don’t!
The only fraud committed was on Du’s part!
Amrn must become a generic company in US and then sell brand name Vascepa OTC!! Then you kill the generics!!
Management gotta make it clear to the generics that OTC is an option!!
Brand, generic and OTC all at once...why not??!!
time for OTC!
A lot of wasted time here over the years!
Every circuit has the ability to review cases en banc. Hearing cases en banc allows the full circuit court to overturn a decision reached by a three–judge panel. Due to the decreasing probability of U.S. Supreme Court intervention, the circuit court is often the court of last resort in the ordinary life of a case, thereby amplifying the importance of en banc review. Despite its significance, many critics contend that en banc review is inefficient and rarely granted.
Each circuit has enacted its own rules governing en banc procedure. These rules have both slight and significant differences from one another and from Federal Rule of Appellate Procedure 35, which governs all of the circuits’ en banc review procedures. Because of the lack of uniformity across the circuits, the proper application of Rule 35 is unclear.
This Note proposes to change the current en banc landscape by altering the method in which a court will make the decision to sit en banc. This Note suggests that petitions for en banc review should only be raised by judges sua sponte, and the decision of whether to sit en banc should be affirmatively voted on by a lower number of active–duty judges than is now required under the simple
Amarin to contest appeals court panel decision on Vascapa patents https://seekingalpha.com/news/3611512-amarin-to-contest-appeals-court-panel-decision-on-vascapa-patents
Collectively as a group we misled each other.... more like sheep
Lol that was fast!! WTF everyone had this wrong here!!!
Amarin loses appeals court ruling on Vascepa https://seekingalpha.com/news/3611464
We lost just announced
WHAT A SHIT SHOW THIS HAS BEEN OVER THE YEARS!!
So OA is the trial! Lol! Far from over!!
From Raf post 269906
Correction, this filing is not the Generics' appeal but rather a Docketing Statement by Generics for Amarin’s appeal. Again, for clarity, Generics did not appeal. Bullish
SA article is somewhat interesting but his short view is evident in the article especially after a nice trading day Amrn had yesterday! It makes you think why the article now!!
Amarin: No Big Pharma Firm Is Riding To The Rescue https://seekingalpha.com/article/4339960
Yeah me too!! I’m little annoyed with her comments!! Glad I live in Henderson!! Lol
Like I said last week, the recent drop in price because of Judge Du’s decision only benefited the institutions to really load up! Again separating retail from their shares!
I’m with you and feel the pain!! But this management team is very head strong!!
Amarin is going to do what Amarin has always done!! Management is going grind it out and survive!! At our expense!! Guaranteed!!
Who benefits the most from the recent drop and a win on appeal!!
That’s the question that needs be ask!
Billion dollar company brought down because patent was “OBVIOUSNESS”!!
I think we all been played here!!
You’re little confused on what going on here! Put the glue down!!!
The case in the U.S. District Court of Nevada was tried by Judge Miranda Du, and this was her first bench trial. Shifting the burden of proof on Amarin to defend secondary considerations of non-obviousness, instead of pressing the generic companies to prove obviousness pertaining to these considerations may have been a procedural error during the trial
Amarin Corportion Plc: Now Compelling On Ex-U.S. Opportunity And Potential Barriers To Generic Competition https://seekingalpha.com/article/4336280
NAViGAtiNG poSt-JuDGmENt motioNS iN NEVADA StAtE couRt
https://www.nvbar.org/wp-content/uploads/NevLawyer_Jan2012_Post_Judement_Motions.pdf
No not my expertise or fight even though I’ve been a long term investor here!! Just providing information that was requested! Hopefully the legal people in the know are addressing issues behind the scenes!